ARGX-110

ARGX-110 is a first-in-class SIMPLE Antibody™ with broad therapeutic potential across a range of cancers (blood and solid tumors) and severe autoimmune diseases. ARGX-110 has demonstrated a very promising safety profile and initial signs of biological activity in T-cell lymphoma (TCL), renal cell carcinoma, ovarian cancer and mesothelioma. Our current clinical development plan focuses on TCL and nasopharyngeal carcinoma (NPC), two indications with a very high unmet medical need.

Clinical trials

  • Ongoing Phase 1b clinical cohort in TCL patients
    • Phase 1b safety expansion study ongoing aiming to recruit up to 20 relapsed/refractory TCL patients
    • Currently four clinics open in the EU (3 BE and 1 FR)
    • Ongoing clinical trial
    • Interim results presented during the June 2015 ICML conference
       
  • Ongoing Phase 1b cohort in NPC patients
    • Phase 1b safety expansion study ongoing with four patients on study (UZ Gent, BE)
       
  • Clinical activity & safety demonstrated
    • Promising safety profile in 69 patients (blood and solid tumors)
    • Biological response in four TCL-patients: clearance of malignant cells from blood compartment, stabilized disease in skin lesions and lymph nodes and skin lesion shrinkage
 Lugano poster

Preclinical data

  • ARGX-110 modes of action: killing tumor cells via enhanced ADCC and immune checkpoint blockade (MAbs 2014, Silence et al.)
  • ARGX-110 overcomes treatment resistance of leukemia stem cells in chronic myelogenous leukemia (Science Translational Medicine, Riether et al.)
 MAbs 2014, Silence et al.  Science Translational Medicine 2015, Riether et al.

Mode of action

  • Three potential modes of action: inhibition of tumor cell proliferation, elimination of tumor cells and prevention of tumor immune escape
  • SIMPLE Antibody™ potently blocking CD70
  • Highly potent cell killing properties through POTELLIGENT®

Target

  • CD70: novel checkpoint
  • Highly specific to tumors, negligable expression on healthy cells
  • Therapeutic effect selective for cancer cells
 Adv Exp Med Biol 2009, Grewal et al.

Indications

  • T-cell Lymphoma (TCL)

    Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). 

    Lymphoma occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. Cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, or other organs, and form tumors. T-cell lymphomas account for approximately 15% of all NHLs in the United States. There are many different forms of T-cell lymphomas, some of which are extremely rare. T-cell lymphomas can be aggressive (fast-growing) or indolent (slow-growing). (Source: American Cancer Society)

  • AML

    Most cases of AML develop from cells that would turn into white blood cells (other than lymphocytes), but some cases of AML develop in other types of blood-forming cells.

    AML starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but in most cases it quickly moves into the blood. It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles.

  • Nasopharyngeal cancer (NPC)

    Nasopharyngeal carcinoma is cancer that occurs in the nasopharynx, which is located behind your nose and above the back of your throat. 

    Nasopharyngeal carcinoma is rare in the United States, where it accounts for approximately 1% of all childhood malignancies, in other parts of the world, specifically Southeast Asia, nasopharyngeal carcinoma occurs much more frequently. Whereas almost all adult nasopharyngeal cancers are carcinomas, only 35-50% of nasopharyngeal malignancies are carcinomas in children. (Source: American Cancer Society).

  • Chronic myelogenous leukemia (CML)

    CML is a cancer of the white blood cells.

    It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is now largely treated with targeted drugs called tyrosine kinase inhibitors (TKIs). In Western countries it accounts for 15-20% of all adult leukemias and 14% of leukemias overall (including the pediatric population). (Source: American Cancer Society)